Journal of Clinical Oncology 临床肿瘤· Saurabh Zanwar·· 2 天前AI 评分35
CHARGE 预后指数在复发/难治性多发性骨髓瘤患者中 Bispecific T-Cell Engagers 早期治疗失败的开发与验证
Early Treatment Failure in Patients With Relapsed/Refractory Multiple Myeloma Receiving Bispecific T-Cell Engagers: Development and Validation of the CHARGE Prognostic Index
AI 导读
研究开发并验证了 CHARGE 预后指数,用于评估复发/难治性多发性骨髓瘤患者接受 Bispecific T-Cell Engagers 治疗的早期失败风险。
来源:Journal of Clinical Oncology 临床肿瘤 · ascopubs.org